Human Metabolome Technologies (6090) · InitiativeRestated
Launch and sales expansion of the “Metabolomics Index” biomarker discovery service
First written in FY2022-Q2. 1 of 2 entries say "Restated". Latest entry: FY2022-Q3.
2entries
1years
0from disclosures
How it moved
Same theme, other companies
Expansion from Biomarker Research into Diagnostic Reagents and Epidemiology ServicesA theme 6 companies write about · 0 as a headwind · 12 as a tailwind
1 other company's latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2022-Q3RestatedAnnual report
「The company also continued efforts to develop its biomarker discovery service and promote R&D to support the development of healthcare solutions.」
The company has continued developing its biomarker discovery service and conducting R&D to support healthcare solution development. - FY2022-Q2First statedAnnual report
「We launched Metabolome Index in December as a biomarker discovery service and will work to expand sales of the service going forward.」
The company launched Metabolome Index as a biomarker discovery service in December and identified future sales expansion as an initiative.